Regulation of androgen-dependent prostatic cancer cell growth: Androgen regulation of CDK2, CDK4, and CKI p16 genes

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4511-4516

  Lu, Shan ^a   Tsai, Sophia Y ^a   Tsai, Ming Jer ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ARTICLE; CANCER GROWTH; GENE CONTROL; GROWTH REGULATION; HORMONAL CARCINOGENESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA;

ADENOCARCINOMA; CDC2-CDC28 KINASES; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA PROBES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; KINETICS; MALE; METRIBOLONE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TESTOSTERONE CONGENERS; TUMOR CELLS, CULTURED;

EID: 0030876442     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Boring, C. C., Squires, T. S., and Tong, T. Cancer statistics, 1993. CA Cancer J. Clin., 43: 7-26, 1993.
2. Hakimi, J. M., Rondinelli, R. H., Schownberg, M. P., and Barrack, E. R. Androgen receptor in human prostate cancer: heterogeneous expression, gene mutations, and polymorphic variants. In: W. V. Vedeckis (ed.), Hormone and Cancer, pp. 445-492. Boston: Birkhauser, 1996.
3. Isaacs, J. T. Role of androgens in prostatic cancer. Vitam. Horm., 49: 433-502, 1994.
4. Huggins, C., and Johnson, M. Carcinoma of the bladder and prostate. J. Am. Med. Assoc., 135: 1146-1152, 1947.
5. van Steenbrugge, G. J., van Uffelen, C. J., Bolt, J., and Schroder, F. H. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J. Steroid Biochem. Mol. Biol., 40: 207-214, 1991.
6. Kokontis J., Ito, K., Hiipakka, R. A., and Liao, S. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells: altered hormone and antihormone specificity in gene transactivation. Receptor. 1: 271-279, 1991.
7. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
8. Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., and Barrack, E. R. Androgen receptor gene mutations in human prostate cancer. Proc. Natl. Acad. Sci. USA, 89: 6319-6323, 1992.
9. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
10. Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., Higgins, S. J., and Sugimura, Y. The endocrinology and developmental biology of the prostate. Endocr. Rev., 8: 338-362, 1987.
11. Berges, R. R., Furuya, Y., Remington, L., English, H. F., Jacks, T., and Isaacs, J. T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA, 90: 8910-8914, 1993.
12. Isaacs, J. T., Lundmo, P. I., Berges, R., Martikainen, P., Kyprianou, N., and English, H. F. Androgen regulation of programmed death of normal and malignant prostatic cells, J. Androl., 13: 457-464, 1992.
13. Mooradian, A. D., Morley, J. E., and Korenman, S. G. Biological actions of androgens. Endocr. Rev., 8: 1-28, 1987.
14. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Brinkmann, A. O., and Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen-responsive element. Mol. Endocrinol., 5: 1921-1930, 1991.
15. Tan, J. A., Marschke, K. B., Ho, K. C., Perry, S. T., Wilson, E. M., and French, F. S. Response elements of the androgen-regulated C3 gene. J. Biol. Chem., 267: 4456-4466, 1992.
16. Adler, A. J., Scheller, A., Hoffman, Y., and Robins, D. M. Multiple components of a complex androgen-dependent enhancer. Mol. Endocrinol., 5: 1587-1596, 1991.
17. Rennie, P. S., Bruchovsky, N., Leco, K. J., Sheppard, P. C., McQueen, S. A., Cheng, H., Snoek, R., Hamel, A., Bock, M. E., MacDonald, B. S., Nickel, B. E., Chang, C., Liao, S., Cattini, P. A., and Matusik, R. J. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol. Endocrinol., 7: 23-36, 1993.
18. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573-582, 1994.
19. Dong, Z. Y., Ward, N. E., Fan, D., Gupta, K. P., and O'Brian, C. A. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol. Pharmacol., 39: 563-569, 1991.
20. Tilley, W. D., Bentel, J. M., Aspinall, J. O., Hall, R. E., and Horsfall, D. J. Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line PC-3. Steroids, 60: 180-186, 1995.
21. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res., 55: 2988-2994, 1995.
22. Veldscholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Trapman, J., Brinkmann, A. O., and Mulder, E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol., 41: 665-669, 1992.
23. Grana, X., and Reddy, E. P. Cell cycle control in mammalian cells: role of cyclins. cyclin-dependent kinases (CDKs), growth suppressor genes, and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11: 211-219, 1995.
24. 1 progression. Oncogene, 9: 2663-2674, 1994.
25. Khatib, Z. A. Matsushime, H., Valentine, M., Shapiro, D. N., Sherr, C. J., and Look, A. T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53: 5535-5541, 1993.
26. 1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
27. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAFI, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
28. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
29. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
30. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.
31. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639-649, 1995.
32. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
33. Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
34. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
35. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
36. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
37. INK4B/ MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939-2952, 1994.
38. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
39. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S. R., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
40. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek, J. Retinoblastoma-protein-dependent cell cycle inhibition by the tumor suppressor p16. Nature (Lond.), 375: 503-506, 1995.
41. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature (Lond.), 375: 506-510, 1995.
42. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
43. Sadi, M. V., Walsh, P. C., and Barrack, E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer: comparison of receptor content and response to hormonal therapy. Cancer (Phila.), 67: 3057-3064, 1991.
44. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
45. Ikonen, T., Palvimo, J. J., Kallio, P. J., Reinikainen, P., and Janne, O. A. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology, 135: 1359-1366, 1994.
46. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bausch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.